HighGravityDataMolina Healthcare — Apr 23, 2025 release
Fiscal 2025 first-quarter results · 8-K Item 2.02 · Exhibit 99.1 · 0001179929-25-000067
Showing in the filing
Non-recurring acquisition-related costs estimate
“approximately $23 million”
Period
No period stated
Measure
Company-defined measure
Source
Prose
All guidance in this release · 15
Premium revenue for FY2025
“approximately $42 billion”
Adjusted earnings for FY2025
“at least $24.50 per diluted share”
Adjusted net income Per Diluted Share (2025) for FY2025
“$ 24.50”
New Store Embedded Earnings for FY2026
“$8.65 per diluted share”
Long-term adjusted EPS growth target for the long term
“13% to 15%”
GAAP earnings per share for FY2025
“at least $22.32 per share”
GAAP EPS for FY2025
“at least $22.32 per share”
GAAP Net income Per Diluted Share (2025) for FY2025
“$ 22.32”
Adjusted earnings per share for FY2025
“at least $24.50 per share”
Adjusted EPS growth for FY2025
“8% growth over the full year 2024”
GAAP Net income (2025) for FY2025
“$ 1,208”
Adjusted net income (2025) for FY2025
“$ 1,325”
Statutory tax rate assumption for FY2025
“approximately 23.7%”
Diluted weighted average shares outstanding … for FY2025
“approximately 54.1 million”
Non-recurring acquisition-related costs esti…
“approximately $23 million”
Exhibit 99.1 · the passage around this item
… earlier in the release
Management is unable to reconcile this measure to the growth in GAAP earnings per share, the most directly comparable GAAP measure, without unreasonable effort due to the unknown impact from the amortization of intangible assets related to recently announced acquisitions, which cannot be determined until purchase accounting valuations are completed. Non-recurring costs associated with the recently announced acquisitions are estimated at approximately $23 million. -END-
the item shown at left
other guidance in this release
Text is the filed exhibit, verbatim.